Shares of Zydus Lifesciences Ltd surged over 6% in Tuesday’s trade after the pharmaceutical major announced a ₹1,100 crore share buyback alongside strong March quarter earnings.
The stock climbed as much as 5.8% to ₹1,048 on the NSE, nearing its 52-week high of ₹1,059.05. Trading volumes also remained elevated during the session.
Investor sentiment received a boost after the company approved a buyback of up to 95.65 lakh equity shares at ₹1,150 per share through the tender offer route. The buyback price implies a premium over the previous closing price and signals management confidence in the company’s long-term outlook.
Apart from the buyback announcement, Zydus also reported a healthy operational performance for the quarter ended March 31, 2026.
The company posted consolidated net profit of ₹1,272.5 crore in Q4 FY26, up 8.7% year-on-year from ₹1,170.9 crore reported in the corresponding quarter last year.
Revenue from operations rose 16.2% YoY to ₹7,587 crore during the March quarter, compared to ₹6,527.9 crore a year ago.
Operationally, EBITDA stood at ₹2,554 crore in Q4 FY26 against ₹2,125.5 crore in the year-ago quarter, while EBITDA margin improved to 33.7% from 32.6%.
The company also fixed May 29, 2026, as the record date for determining shareholder eligibility for participation in the buyback offer.
Market participants appeared to cheer both the strong earnings growth and the sizeable shareholder reward announcement, helping the stock outperform broader markets in intraday trade.